We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · June 06, 2022

Outcomes of Adding ADT and Pelvic Lymph Node Treatment to Prostate Bed Salvage Radiotherapy for Prostate Cancer

The Lancet


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial
Lancet 2022 May 14;399(10338)1886-1901, A Pollack, TG Karrison, AG Balogh, LG Gomella, DA Low, DW Bruner, JS Wefel, AG Martin, JM Michalski, SJ Angyalfi, H Lukka, SL Faria, GB Rodrigues, MC Beauchemin, RJ Lee, SA Seaward, AM Allen, DC Monitto, W Seiferheld, O Sartor, F Feng, HM Sandler

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading